By targeting the upstream determinants of mesenchymal expression, such as TGF-β and FOXL1 or by targeting the downstream drivers of BMP signaling such as GREM1 and ISLR, one may identify new approaches to prevent and treat cancer. This evidence concerns the gene TGFB1 and cancer.